PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22186622-10	2012	This study reveals a novel action of ISLQ as a potent CFTR inhibitor with therapeutic potential for treatment of cholera and polycystic kidney disease.	isoliquiritigenin	37-41	CF transmembrane conductance regulator	Homo sapiens	54-58	
22186622-6	2012	Apical Cl(-) current analysis of T84 cell monolayers indicated that ISLQ blocked mainly the cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channels, but not other unidentified cAMP-dependent Cl(-) channels.	isoliquiritigenin	68-72	CF transmembrane conductance regulator	Homo sapiens	92-143	
22186622-6	2012	Apical Cl(-) current analysis of T84 cell monolayers indicated that ISLQ blocked mainly the cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channels, but not other unidentified cAMP-dependent Cl(-) channels.	isoliquiritigenin	68-72	CF transmembrane conductance regulator	Homo sapiens	145-149	
31444000-2	2019	Isoliquiritigenin (ISLQ), a plant-derived chalcone, has previously been shown to exert anti-secretory action in vitro and in vivo by inhibiting CFTR Cl- channels.	isoliquiritigenin	0-17	CF transmembrane conductance regulator	Homo sapiens	144-148	
31444000-2	2019	Isoliquiritigenin (ISLQ), a plant-derived chalcone, has previously been shown to exert anti-secretory action in vitro and in vivo by inhibiting CFTR Cl- channels.	isoliquiritigenin	19-23	CF transmembrane conductance regulator	Homo sapiens	144-148